Experimental drug reduces brain damage, eliminates brain hemorrhaging in rodents afflicted by stroke ( University of Southern California - Health Sciences ) Developed by a team led by USC physician-scientist Berislav V. Zlokovic, the experimental drug 3K3A-APC shows promise as a stand-alone therapy for stroke or in combination with the FDA-approved clot-busting drug therapy tPA (tissue plasminogen activator).
Oct. 25, 2013 - EurekAlert!